Infection with SARS-CoV-2 results in clinical outcomes ranging from silent or benign
infection in most individuals to critical pneumonia and death in a few. Genetic studies in …

Host immunity to infection with SARS-CoV-2 is highly variable, dictating diverse clinical
outcomes ranging from asymptomatic to severe disease and death. We previously reported …

Type I and type III interferons are among the most potent anti-viral cytokines produced by the
immune system. The recent outbreak of SARS-CoV-2, which causes COVID-19 …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative agent of
coronavirus disease 2019 (COVID‐19), has caused millions of deaths in the past two years …

ABSTRACT SARS-CoV-2, a novel coronavirus (CoV) that causes COVID-19, has recently
emerged causing an ongoing outbreak of viral pneumonia around the world. While distinct …

Infection with SARS-CoV-2 can lead to excessive production of pro-inflammatory cytokines,
but the production of type I interferons, which are key antiviral mediators, is reportedly …

Type I interferons (IFNs) are our first line of defense against virus infection. Recent studies
have suggested the ability of SARS-CoV-2 proteins to inhibit IFN responses. Emerging data …

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the
current COVID-19 pandemic. An unbalanced immune response, characterized by a weak …

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay
between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro …

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The ability of our cells to secrete type I …